These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 23328943)

  • 1. Update on the treatment of Duchenne muscular dystrophy.
    Rodino-Klapac LR; Mendell JR; Sahenk Z
    Curr Neurol Neurosci Rep; 2013 Mar; 13(3):332. PubMed ID: 23328943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.
    Wilton SD; Fletcher S
    Curr Pharm Des; 2010; 16(8):988-1001. PubMed ID: 20041827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy.
    D'Ambrosio ES; Mendell JR
    Neurotherapeutics; 2023 Oct; 20(6):1669-1681. PubMed ID: 37673849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy.
    Yokota T; Pistilli E; Duddy W; Nagaraju K
    Expert Opin Biol Ther; 2007 Jun; 7(6):831-42. PubMed ID: 17555369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD).
    Kawecka K; Theodoulides M; Hasoglu Y; Jarmin S; Kymalainen H; Le-Heron A; Popplewell L; Malerba A; Dickson G; Athanasopoulos T
    Curr Gene Ther; 2015; 15(4):395-415. PubMed ID: 26159373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less is more: therapeutic exon skipping for Duchenne muscular dystrophy.
    Aartsma-Rus A; van Ommen GJ
    Lancet Neurol; 2009 Oct; 8(10):873-5. PubMed ID: 19713153
    [No Abstract]   [Full Text] [Related]  

  • 8. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
    Touznik A; Lee JJ; Yokota T
    Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of exon skipping for treatment for Duchenne muscular dystrophy.
    Partridge T
    J Child Neurol; 2010 Sep; 25(9):1165-70. PubMed ID: 20519674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].
    Takeda S
    Rinsho Shinkeigaku; 2009 Nov; 49(11):856-8. PubMed ID: 20030230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.
    Guiraud S; Chen H; Burns DT; Davies KE
    Exp Physiol; 2015 Dec; 100(12):1458-67. PubMed ID: 26140505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for antisense modulation of dystrophin pre-mRNA splicing.
    Dickson G; Hill V; Graham IR
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S67-70. PubMed ID: 12206799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of novel therapeutic approaches for Duchenne muscular dystrophy].
    Takeshima Y
    No To Hattatsu; 2014 Mar; 46(2):109-14. PubMed ID: 24738186
    [No Abstract]   [Full Text] [Related]  

  • 19. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
    Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K
    Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.